News - Page 106 - Psychedelic Alpha

Introducing The Psychedelic Practitioner, a new publication by Psychedelic Alpha.

Read more about the article Incannex announces positive results from phase 2 clinical trial investigating the effect of IHL-42X for treatment of obstructive sleep apnoea

Incannex announces positive results from phase 2 clinical trial investigating the effect of IHL-42X for treatment of obstructive sleep apnoea

Post published:June 3, 2022
Post category:Press Release

Read more about the article Ehave, Inc. Announces its KetaDASH Mobile Unit will be Delivered to Miami Beach on June 10, 2022

Ehave, Inc. Announces its KetaDASH Mobile Unit will be Delivered to Miami Beach on June 10, 2022

Post published:June 3, 2022
Post category:Press Release

Read more about the article Psychedelic Research Bulletin: May 2022

Psychedelic Research Bulletin: May 2022

Post published:June 2, 2022
Post category:Psychedelics Research Review

Read more about the article Psyence Group Corporate Update

Psyence Group Corporate Update

Post published:June 2, 2022
Post category:Press Release

Read more about the article PsyBio Therapeutics Initiates Commercial Biosynthetic Based Process Development for Psycho-Targeted and Psychoactive Compounds

PsyBio Therapeutics Initiates Commercial Biosynthetic Based Process Development for Psycho-Targeted and Psychoactive Compounds

Post published:June 2, 2022
Post category:Press Release

Read more about the article Mindmed Announces Voting Results for Annual General and Special Meeting

Mindmed Announces Voting Results for Annual General and Special Meeting

Post published:June 1, 2022
Post category:Press Release

Read more about the article Psychedelic Bulletin #104 – Mydecine CEO Downplays Insider Activity; UC Davis Scores $2.7m to Study Non-hallucinogenic Psychedelics; Oregon Health Authority Adopts Rules

Psychedelic Bulletin #104 – Mydecine CEO Downplays Insider Activity; UC Davis Scores $2.7m to Study Non-hallucinogenic Psychedelics; Oregon Health Authority Adopts Rules

Post published:May 27, 2022
Post category:Psychedelic Bulletin

Read more about the article Bright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet Syndrome

Bright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet Syndrome

Post published:May 22, 2022
Post category:Press Release

Read more about the article COMPASS Pathways presents largest ever study of psilocybin therapy, at American Psychiatric Association annual meeting

COMPASS Pathways presents largest ever study of psilocybin therapy, at American Psychiatric Association annual meeting

Post published:May 22, 2022
Post category:Press Release

Read more about the article Psychedelic Bulletin #103 – MAPS Phase 3 Trial On Schedule; Australia’s National Science Agency Working on Psychedelics; Death Spiral Financings

Psychedelic Bulletin #103 – MAPS Phase 3 Trial On Schedule; Australia’s National Science Agency Working on Psychedelics; Death Spiral Financings

Post published:May 22, 2022
Post category:Psychedelic Bulletin

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.